ShanXi C&Y Pharmaceutical GroupLTD Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
ShanXi C&Y Pharmaceutical GroupLTD has a total shareholder equity of CN¥852.4M and total debt of CN¥126.5M, which brings its debt-to-equity ratio to 14.8%. Its total assets and total liabilities are CN¥1.5B and CN¥674.7M respectively. ShanXi C&Y Pharmaceutical GroupLTD's EBIT is CN¥63.7M making its interest coverage ratio 4.7. It has cash and short-term investments of CN¥176.5M.
Anahtar bilgiler
14.8%
Borç/özkaynak oranı
CN¥126.51m
Borç
| Faiz karşılama oranı | 4.7x |
| Nakit | CN¥176.48m |
| Eşitlik | CN¥852.39m |
| Toplam yükümlülükler | CN¥674.68m |
| Toplam varlıklar | CN¥1.53b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 300254's short term assets (CN¥479.5M) do not cover its short term liabilities (CN¥569.5M).
Uzun Vadeli Yükümlülükler: 300254's short term assets (CN¥479.5M) exceed its long term liabilities (CN¥105.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 300254 has more cash than its total debt.
Borcun Azaltılması: 300254's debt to equity ratio has reduced from 35.3% to 14.8% over the past 5 years.
Borç Kapsamı: 300254's debt is well covered by operating cash flow (71.2%).
Faiz Kapsamı: 300254's interest payments on its debt are well covered by EBIT (4.7x coverage).